ES2807781T3 - Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1 - Google Patents

Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1 Download PDF

Info

Publication number
ES2807781T3
ES2807781T3 ES19160815T ES19160815T ES2807781T3 ES 2807781 T3 ES2807781 T3 ES 2807781T3 ES 19160815 T ES19160815 T ES 19160815T ES 19160815 T ES19160815 T ES 19160815T ES 2807781 T3 ES2807781 T3 ES 2807781T3
Authority
ES
Spain
Prior art keywords
protein
diet
day
subject
diet composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19160815T
Other languages
English (en)
Spanish (es)
Inventor
Valter D Longo
Sebastian Brandhorst
Morgan Elyse Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2807781T3 publication Critical patent/ES2807781T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pediatric Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
ES19160815T 2013-02-12 2014-02-12 Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1 Active ES2807781T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12

Publications (1)

Publication Number Publication Date
ES2807781T3 true ES2807781T3 (es) 2021-02-24

Family

ID=51297596

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19160815T Active ES2807781T3 (es) 2013-02-12 2014-02-12 Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1

Country Status (12)

Country Link
US (3) US9237761B2 (cg-RX-API-DMAC7.html)
EP (2) EP2956776A4 (cg-RX-API-DMAC7.html)
JP (2) JP6885671B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150124962A (cg-RX-API-DMAC7.html)
CN (3) CN114236130A (cg-RX-API-DMAC7.html)
AU (3) AU2014216349B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015019223A2 (cg-RX-API-DMAC7.html)
CA (1) CA2900782C (cg-RX-API-DMAC7.html)
ES (1) ES2807781T3 (cg-RX-API-DMAC7.html)
MX (1) MX382484B (cg-RX-API-DMAC7.html)
RU (2) RU2018141475A (cg-RX-API-DMAC7.html)
WO (1) WO2014127000A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10015980B2 (en) 2012-10-22 2018-07-10 University Of Southern California Methods and formulations promoting tissue/organ regeneration, longevity and healthspan
KR20150124962A (ko) * 2013-02-12 2015-11-06 유니버시티 오브 써던 캘리포니아 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식
MX381340B (es) 2013-07-01 2025-03-12 Univ Southern California Dieta para diabetes basada en sistema de ayuno.
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
CA2944479C (en) 2014-04-02 2023-02-21 University Of Southern California Dietary formulation and method for treating autoimmune and inflammatory diseases
BR112017017182A2 (pt) 2015-02-12 2018-04-03 Univ Southern California composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento
US20160303056A1 (en) * 2015-04-16 2016-10-20 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
BR112017023748A2 (pt) * 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
CA3009664C (en) * 2016-01-12 2024-02-13 University Of Southern California Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
AU2017219732B2 (en) 2016-02-15 2022-01-20 University Of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
EP3454867B1 (en) 2016-05-11 2021-03-24 University of Southern California Fasting mimicking diet (fmd) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN112153974A (zh) 2018-03-15 2020-12-29 南加利福尼亚大学 禁食模仿膳食(fmd)而非仅饮水禁食促进炎症和ibd病理学的逆转
US20210267250A1 (en) 2018-07-18 2021-09-02 Andreas Michalsen Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
JP2020059699A (ja) * 2018-10-04 2020-04-16 株式会社明治 難治性癌の食事療法およびそれに適した治療食
BR112021008998A2 (pt) 2018-11-09 2021-08-10 L-Nutra barra alimentar para simulação de jejum intermitente
CN114096164A (zh) 2019-04-30 2022-02-25 南加利福尼亚大学 作为阿尔茨海默病(ad)的干预措施的禁食模拟饮食(fmd)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
US20230037534A1 (en) * 2019-12-16 2023-02-09 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
EP4076458A1 (en) 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
IT202000008740A1 (it) * 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
US20230329304A1 (en) * 2020-09-23 2023-10-19 Aminovita S.L. Metabolic therapy of cancer
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
US20250177466A1 (en) * 2022-08-23 2025-06-05 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
US20250194656A1 (en) * 2023-12-14 2025-06-19 L-Nutra Inc. Longevity extending consumable products for maximizing strength and function, methods of consumption and manufacture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
KR20040026665A (ko) * 2001-06-15 2004-03-31 인터레우킨 제네틱스, 인코포레이티드 노화 관련 증상의 조기 개시를 검출 및 치료하는 방법
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
US20100022451A1 (en) * 2004-12-27 2010-01-28 Nestec S.A. Use of infant formula with reduced protein content
WO2007088046A2 (en) * 2006-02-01 2007-08-09 Nestec S.A. Nutritional system and methods for increasing longevity
ES2800327T3 (es) * 2008-04-24 2020-12-29 Univ Of Southern California Usc Stevens Composiciones dietéticas y métodos de protección contra la quimioterapia o radioterapia
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
PL2490684T3 (pl) * 2009-10-22 2018-07-31 University Of Southern California Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu
US10015980B2 (en) * 2012-10-22 2018-07-10 University Of Southern California Methods and formulations promoting tissue/organ regeneration, longevity and healthspan
KR20150124962A (ko) * 2013-02-12 2015-11-06 유니버시티 오브 써던 캘리포니아 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식

Also Published As

Publication number Publication date
HK1212028A1 (en) 2016-06-03
EP3510875A1 (en) 2019-07-17
JP6885671B2 (ja) 2021-06-16
EP3510875B1 (en) 2020-06-10
MX382484B (es) 2025-03-13
CA2900782C (en) 2022-09-27
AU2020200297B2 (en) 2022-04-07
CN114236130A (zh) 2022-03-25
RU2015134780A (ru) 2017-03-20
RU2674681C2 (ru) 2018-12-12
WO2014127000A2 (en) 2014-08-21
CA2900782A1 (en) 2014-08-21
CN109187991A (zh) 2019-01-11
JP2020073473A (ja) 2020-05-14
CN105008929B (zh) 2018-10-02
US20140227373A1 (en) 2014-08-14
EP2956776A4 (en) 2016-12-21
KR20150124962A (ko) 2015-11-06
AU2014216349B2 (en) 2019-10-24
AU2022202764A1 (en) 2022-05-19
AU2014216349A1 (en) 2015-08-06
JP2016509994A (ja) 2016-04-04
CN109187991B (zh) 2021-12-24
BR112015019223A2 (pt) 2017-07-18
MX2015010320A (es) 2016-06-02
RU2018141475A (ru) 2019-03-21
EP2956776A2 (en) 2015-12-23
US20160331016A1 (en) 2016-11-17
US9237761B2 (en) 2016-01-19
RU2018141475A3 (cg-RX-API-DMAC7.html) 2022-03-29
CN105008929A (zh) 2015-10-28
US20170035094A1 (en) 2017-02-09
AU2020200297A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
ES2807781T3 (es) Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1
Brandhorst et al. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression
RU2549954C2 (ru) Способы и диетологические составы для повышения эффективности и снижения побочных эффектов лечения рака
ES2822178T3 (es) Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
RU2734774C2 (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
ES2555860T3 (es) Combinación de una fuente de leucina y una fuente de ácido graso omega-3 insaturado para uso en el tratamiento de hipercalcemia
Phalle et al. Maternal and fetal outcomes in gestational diabetes mellitus: a narrative review of dietary interventions
Boirie Whey protein and muscle protection
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法
HK40002950A (en) Method for providing reasonable protein diet to subject
HK1212028B (en) Methods and diets to protect against chemotoxicity and age related illnesses
Télessy Research Article Advances in Nutrition and Food Science ANAFS-160